Emoton (sertralin) coated tablets 50 mg. №30


Manufacturer: Ukraine

Treatment of symptoms of depression (including agitated, regardless of the presence or absence of mania in the history); treatment of obsessive-compulsive disorders (obsessions), including in children; panic disorders (with or without agoraphobia); treatment of post-traumatic stress disorder; anxiety States and manifestations of social phobia (social anxiety disorder), as well as prevention of their relapses.



Emoton Storage
active substance: sertraline;

1 film-coated tablet contains sertraline hydrochloride 50 mg or 100 mg;

Emoton Excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate;

the film shell contains: polyvinyl alcohol, titanium dioxide (E 171), polyethylene glycol 300, talc.

Emoton Dosage form
Film-coated tablets.

Basic physical and chemical properties: white rounded, convex tablets with a line.

Pharmacotherapeutic group
Antidepressants. Selective serotonin reuptake inhibitors. ATX code N06A B06.

Pharmacological properties


Sertraline is a potent and specific inhibitor of neuronal serotonin uptake (5-HT) in vitro, which potentiates the effects of 5-HT in animals. Sertraline has only a very weak effect on the processes of neuronal reuptake of norepinephrine and dopamine. At clinical doses, sertraline blocks the uptake of serotonin into human platelets. The drug has no stimulating, sedative, anticholinergic or cardiotoxic effects in animal experiments. Sertraline did not have a sedative effect and did not affect psychomotor functions during the use of the drug. According to its inherent selective inhibition of serotonin reuptake, sertraline does not stimulate catecholaminergic activity. The drug has no affinity for muscarinic (cholinergic), serotonergic, dopaminergic, adrenergic, histaminergic, GABA or benzodiazepine receptors.

Sertraline does not lead to drug dependence. In a comparative study of the potential for abuse of sertraline, alprazolam and d-amphetamine in humans, sertraline did not cause positive subjective effects that would indicate a tendency to abuse. In contrast, study participants who received both alprazolam and d-amphetamine had statistically significantly higher rates of abuse, euphoria, and potential drug dependence compared with placebo. Sertraline does not show a stimulating effect and does not cause anxiety, characteristic of d-amphetamine, or sedative and psychomotor disorders characteristic of alprazolam.

Major depressive episodes. Prevention of recurrence of major depressive episodes.
Panic disorders with or without agoraphobia.
Obsessive-compulsive disorder (OCD) in adults and children aged 6-17 years.
Social anxiety disorder.
Post-traumatic stress disorder (PTSD).

Hypersensitivity to sertraline or to other components of the drug. Severe liver dysfunction; uncontrolled epilepsy. Concomitant use of monoamine oxidase inhibitors (MAOIs). Concomitant use of sertraline and pimozide is contraindicated.